Your browser doesn't support javascript.
loading
CRISPR/Cas9 in the era of nanomedicine and synthetic biology.
Schmidt, Tiziana Julia Nadjeschda; Berarducci, Barbara; Konstantinidou, Soultana; Raffa, Vittoria.
Affiliation
  • Schmidt TJN; Department of Biology, University of Pisa, SS12 Abetone e Brennero 4, 56127 Pisa, Italy.
  • Berarducci B; Department of Biology, University of Pisa, SS12 Abetone e Brennero 4, 56127 Pisa, Italy.
  • Konstantinidou S; Department of Biology, University of Pisa, SS12 Abetone e Brennero 4, 56127 Pisa, Italy.
  • Raffa V; Department of Biology, University of Pisa, SS12 Abetone e Brennero 4, 56127 Pisa, Italy. Electronic address: vittoria.raffa@unipi.it.
Drug Discov Today ; 28(1): 103375, 2023 01.
Article in En | MEDLINE | ID: mdl-36174966
ABSTRACT
The CRISPR/Cas system was first discovered as a defense mechanism in bacteria and is now used as a tool for precise gene-editing applications. Rapidly evolving, it is increasingly applied in therapeutics. However, concerns about safety, specificity, and delivery still limit its potential. In this context, we introduce the concept of nanogenetics and speculate how the rational engineering of the CRISPR/Cas machinery could advance the biomedical field. In nanogenetics, the advantages of traditional approaches of synthetic biology could be expanded by nanotechnology approaches, enabling the design of a new generation of intrinsically safe and specific genome-editing platforms.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanomedicine / CRISPR-Cas Systems Language: En Journal: Drug Discov Today Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanomedicine / CRISPR-Cas Systems Language: En Journal: Drug Discov Today Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: